Clinical Guideline Briefing
LANCETP
Algorithmic Treatment Of Schizophrenia
2025
Published May 18, 2026
10 min read
LANCETP launches 2025 guideline for Algorithmic Treatment of Schizophrenia
New international guidelines emphasize proactive metabolic health management from treatment initiation and earlier consideration of clozapine for treatment resistance.
Headline change
The guideline advocates for proactive metabolic health management, including metformin co-initiation with high-risk antipsychotics, and earlier consideration of clozapine for treatment-resistant positive symptoms.
Bedside action
Implement comprehensive baseline metabolic screening for all patients starting antipsychotics, and be prepared to discuss D2 partial agonists as initial therapy or metformin co-initiation with olanzapine or clozapine.
The INTEGRATE guidelines represent a significant international consensus on the pharmacological treatment of schizophrenia, addressing the need for a concise, algorithmic approach. This briefing highlights key shifts towards individualized care, early intervention for non-response, and comprehensive metabolic health management from the outset, aiming to improve long-term patient outcomes.
How It Compares Across Societies
The INTEGRATE guidelines offer a refined, algorithmic approach compared to earlier consensus documents like the WFSBP 2013 guidelines, particularly in the proactive management of side effects and treatment resistance.
WFSBP 2013-1 / 2013-2
WFSBP 2013-1 / 2013-2
Clozapine should be introduced as the treatment of choice for clearly defined treatment-resistant schizophrenia, typically after two different antipsychotics from at least two different chemical classes (2-8 weeks each).
This guideline
Consider a trial of clozapine if positive symptoms remain significant after two antipsychotic treatments (each for 4 weeks at therapeutic dose with good adherence).
Why they differINTEGRATE provides a more explicit algorithmic pathway and timeline for considering clozapine, suggesting an earlier, more structured approach to treatment resistance.
For the clinicianClinicians following INTEGRATE may initiate clozapine trials sooner in patients with persistent positive symptoms after two failed antipsychotic regimens.
WFSBP 2013-1 / 2013-2
WFSBP 2013-1 / 2013-2
Antipsychotic drugs should not be prescribed concurrently, and monotherapy should be favored, with combination treatment acceptable only for short periods during switching or in severe treatment resistance.
This guideline
The guidelines do not discuss polypharmacy other than in the case of aripiprazole augmentation or the augmentation of clozapine.
Why they differINTEGRATE acknowledges and implicitly supports specific, evidence-based augmentation strategies, while WFSBP generally advises against antipsychotic polypharmacy.
For the clinicianINTEGRATE provides clearer guidance for specific augmentation strategies (e.g., aripiprazole or clozapine augmentation), whereas WFSBP is more cautious about polypharmacy in general.
WFSBP 2013-1
WFSBP 2013-1
Second-generation antipsychotics (SGAs) should be favored in first-episode schizophrenia patients due to a reduced risk of extrapyramidal side effects, but first-generation antipsychotics (FGAs) also have a place.
This guideline
If no patient preference is expressed for an initial antipsychotic, a D2 partial agonist (e.g., aripiprazole) with a lower overall side-effect burden is recommended.
Why they differINTEGRATE offers a more specific recommendation for initial antipsychotic choice based on side-effect burden when patient preference is absent, whereas WFSBP provides a broader class-level preference.
For the clinicianClinicians following INTEGRATE may be more inclined to select a D2 partial agonist like aripiprazole as a first-line option in the absence of patient preference.
WFSBP 2013-1 / 2013-2
WFSBP 2013-1 / 2013-2
Monitoring for obesity-related health problems and consideration of appropriate interventions are recommended if necessary, but does not explicitly recommend concomitant metformin at initiation.
This guideline
When initiating antipsychotics with high metabolic adverse event liability (e.g., olanzapine or clozapine), offer concomitant lifestyle modification and metformin to attenuate potential weight gain.
Why they differINTEGRATE adopts a more proactive stance by recommending concomitant metformin at the initiation of high metabolic risk antipsychotics, rather than waiting for metabolic issues to develop.
For the clinicianClinicians should proactively offer metformin alongside olanzapine or clozapine from the start, rather than only considering it after weight gain or metabolic abnormalities occur.
Where they agree
- Shared decision-making involving patients and carers is essential for treatment planning.
- Antipsychotic medications are the first-line pharmacological treatment for schizophrenia.
- Continuous monitoring for adverse effects, particularly metabolic and neurological, is crucial throughout treatment.
Practice Notes
These practice notes highlight critical considerations for daily clinical management based on the new guidelines.
Shared decision point
Actively involve patients and their carers in all treatment decisions.
Shared decision-making, including discussions on treatment options, risks, benefits, and side-effect profiles, is a foundational principle to improve adherence and outcomes.
Caution
Avoid prolactin-raising antipsychotics, especially in female patients of childbearing age.
These medications can lead to significant endocrine side effects, impacting fertility and bone health, necessitating careful selection or proactive management of hyperprolactinemia.
Monitoring
Obtain a comprehensive set of baseline metabolic and physical health measurements before starting any antipsychotic.
This includes BMI, waist circumference, blood pressure, HbA1c, glucose, lipids, prolactin, LFTs, U+Es, FBC, and ECG, to establish a baseline for ongoing monitoring and early intervention for side effects.
Implementation
Discuss long-acting injectable (LAI) formulations early if adherence to oral medication is a concern.
LAIs can significantly improve adherence and reduce relapse risk, and the option should be presented collaboratively, even without overt non-adherence in cases of non-response or partial response.
Key Recommendations
The INTEGRATE guidelines provide an algorithmic framework for the pharmacological management of schizophrenia, emphasizing individualized care, proactive side-effect mitigation, and timely escalation for non-response. These key recommendations cover the full spectrum of care, from initial treatment to managing treatment resistance and monitoring.
Key recommendations15 highlighted
01
In all individuals diagnosed with schizophrenia and their carers, involve them in shared decision-making for treatment whenever possible, providing information on options, risks, benefits, and seeking feedback.
Line / Strengthshould be done
EvidenceThis is a consensus-based recommendation, informed by expert workshops and lived experience focus groups, and supported by multiple references (9, 11–15) emphasizing patient involvement.
For practicePrioritize collaborative discussions about treatment plans, ensuring patient and carer understanding and input.
CaveatIf a patient is unable to engage in discussion, input from friends and family should be sought, with the patient engaged as soon as clinically feasible.
02
In all patients with schizophrenia, individualize treatment based on current symptoms and patient preferences regarding side-effects, efficacy, and route of administration, considering factors like age, gender, ethnicity, comorbidities, and concomitant medications.
Line / Strengthshould be individualised
EvidenceThis recommendation stems from consensus, acknowledging the variability in patient response and tolerability, and is supported by references (9, 11–19) on individual factors affecting pharmacokinetics and treatment choice.
For practiceTailor antipsychotic selection and dosing to each patient's unique profile, including their pharmacokinetic factors and personal preferences.
CaveatThe cost and availability of treatments might limit options in some settings, requiring adaptation of general principles.
03
In patients initiating, switching, or augmenting antipsychotic treatment, assess treatment effectiveness early and use a proactive approach when adjusting treatment due to inadequate efficacy or poor tolerability.
Line / Strengthshould be assessed
EvidenceA consensus recommendation, highlighting that early assessment and proactive adjustment are crucial for optimizing outcomes, supported by evidence on early improvement as a predictor of response (reference 23).
For practiceSchedule early follow-up (e.g., 1 week) after starting or changing medication to promptly evaluate response and tolerability.
04
In individuals experiencing psychotic symptoms for a week or more with associated distress or functional impairment, offer antipsychotic treatment.
Line / Strengthshould be offered
EvidenceThis is a consensus statement based on the understanding that early intervention in psychosis is beneficial, supported by clinical guidelines (references 24, 25).
For practiceInitiate antipsychotic therapy promptly in first-episode psychosis, especially with severe distress or safety concerns.
CaveatDelay treatment if symptoms are clearly related to substance use or a medical condition and do not pose safety concerns.
05
In patients with first-episode psychosis without a preference for an initial antipsychotic, recommend an antipsychotic with a lower overall side-effect burden, such as a D2 partial agonist (e.g., aripiprazole).
Line / Strengthis recommended
EvidenceConsensus-based, favoring D2 partial agonists due to their generally more benign side-effect profile, as supported by systematic reviews (references 7, 20).
For practiceConsider aripiprazole or similar D2 partial agonists as a first-line option when patients have no specific preference, prioritizing side-effect burden.
CaveatPatient preference should always guide choice if expressed.
06
In female patients of childbearing age, avoid prolactin-raising antipsychotics where possible.
Line / Strengthshould be avoided
EvidenceThis is a consensus-based safety recommendation to mitigate risks of hyperprolactinemia, which can impact reproductive health and bone mineral density.
For practiceCarefully review antipsychotic choice in this population, opting for non-prolactin-raising agents whenever clinically appropriate.
CaveatIf unavoidable, monitor prolactin levels and manage hyperprolactinemia proactively.
07
In patients initiating antipsychotics with high metabolic adverse event liability (e.g., olanzapine or clozapine), offer concomitant lifestyle modification and metformin to attenuate potential weight gain.
Line / Strengthshould be offered
EvidenceConsensus recommendation supported by evidence on metformin's efficacy in attenuating antipsychotic-induced weight gain (references 6, 26–30).
For practiceProactively prescribe metformin and lifestyle counseling from the start for patients on olanzapine or clozapine to prevent metabolic complications.
CaveatAssess renal function before commencing metformin; avoid in those with renal failure.
08
In individuals experiencing their first episode of psychosis, start antipsychotics at a low dose.
Line / Strengthshould be started
EvidenceConsensus-based, recognizing that first-episode patients may be more sensitive to side effects and respond to lower doses (reference 13).
For practiceInitiate antipsychotics cautiously with low doses in first-episode psychosis, titrating up as needed for efficacy and tolerability.
CaveatDose should be increased based on response and tolerability; higher starting doses may be appropriate in multi-episode patients.
09
In patients with estimated adherence to oral medication less than 80% of the prescribed dose, discuss the option of a long-acting injectable (LAI) formulation.
Line / Strengthshould be discussed
EvidenceConsensus-based, considering the benefits of LAIs in improving adherence, reducing relapse risk, and potentially improving overall mortality, balanced against drawbacks (references 41–43).
For practiceProactively explore LAI options with patients where adherence is suboptimal or a concern, framing it as a treatment choice.
CaveatDiscussion should be collaborative and avoid any perception of coercion. May also be considered without overt non-adherence if there is non-response or partial response.
10
In patients on antipsychotic medication, always use the lowest effective antipsychotic dose to reduce the risk of side-effects.
Line / Strengthshould always be used
EvidenceA fundamental principle of pharmacotherapy, supported by general clinical practice and references (e.g., 13) emphasizing side-effect reduction.
For practiceRegularly review and adjust antipsychotic doses to maintain efficacy with the minimal possible side-effect burden.
CaveatDose reduction should be gradual and monitored, especially if symptoms are well controlled.
11
In patients considering antipsychotic medication discontinuation, provide robust individual and family psychoeducation on relapse risks and early signs, and use a gradual taper over at least 6 months with ongoing monitoring.
EvidenceConsensus-based, emphasizing the high risk of relapse upon discontinuation and the need for careful, slow tapering and monitoring (reference 49).
For practiceImplement a structured, slow taper plan for discontinuation, prioritizing patient and family education and close follow-up.
CaveatContinuation of medication may be appropriate despite remission if ongoing risk factors for relapse (e.g., substance use) or serious risk concerns exist.
12
In patients with persistent significant positive symptoms after 4 weeks of a therapeutic antipsychotic dose with good adherence, discuss switching to an alternative antipsychotic, ideally with a different pharmacodynamic profile.
Line / Strengthshould be discussed
EvidenceConsensus-based, reflecting an algorithmic approach to non-response, aiming to find a more effective agent (references 51, 52).
For practiceDo not prolong ineffective treatment; consider a switch to an antipsychotic with a different mechanism if initial treatment fails after an adequate trial.
CaveatShared decision-making based on side-effect profiles should guide the choice. First-generation and second-generation classifications should not solely guide choice.
13
In patients with persistent significant positive symptoms following a second antipsychotic treatment (after 4 weeks at therapeutic dose with good adherence), reassess diagnosis and contributing factors, then consider a trial of clozapine.
Line / Strengthshould be considered
EvidenceConsensus-based, recognizing clozapine's superior efficacy in treatment-resistant schizophrenia (references 63–68) after other options have failed and diagnosis is confirmed.
For practiceAfter two adequate trials of other antipsychotics, clozapine should be a primary consideration for treatment-resistant positive symptoms, following a thorough diagnostic reassessment.
CaveatIf a trial of clozapine is not possible or intolerable, olanzapine treatment can be considered. Clozapine dose should be titrated based on response and tolerability, aiming for specific plasma levels.
14
In patients initiating clozapine, offer metformin concomitantly with clozapine to attenuate potential weight gain.
Line / Strengthshould be offered
EvidenceConsensus recommendation, supported by evidence on metformin's role in mitigating metabolic side effects associated with clozapine (references 6, 26–29).
For practiceIntegrate metformin into the treatment plan from the start for all patients initiating clozapine, unless contraindicated.
CaveatRenal function should be assessed before commencing metformin.
15
In patients before starting antipsychotic treatment, obtain baseline measurements including BMI, waist circumference, blood pressure, HbA1c, glucose, lipids, prolactin, liver function tests, urea and electrolytes, full blood count, and electrocardiogram.
Line / Strengthshould be obtained
EvidenceConsensus-based, emphasizing the importance of a comprehensive health assessment to monitor for and manage potential antipsychotic-related side effects (reference 26).
For practiceConduct a thorough baseline screening to establish a comprehensive health profile before initiating antipsychotic therapy and follow a structured monitoring schedule.
CaveatFasting glucose should be re-checked 4 weeks after initiation. BMI, waist circumference, and blood pressure should be checked weekly for 6 weeks, then after 3 months, and annually thereafter.
